

14 - References

References

Pharmacokinetics CHAPTER 11 References

1. Jakobsen MI, et al. The significance of sampling time in therapeutic drug monitoring of clozapine. *Acta Psychiatr Scand* 2017; 135:159-169.
2. Hiemke C. Concentration-effect relationships of psychoactive drugs and the problem to calculate therapeutic reference ranges. *Ther Drug Monit* 2019; 41:174-179.
3. Hart XM, et al. Update lessons from positron emission tomography imaging Part I: a systematic critical review on therapeutic plasma concentrations of antipsychotics. *Ther Drug Monit* 2024; 46:16-32.
4. Kapur S, et al. Relationship between dopamine D2 occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia. *Am J Psychiatry* 2000; 157:514-520.
5. Kronig MH, et al. Plasma clozapine levels and clinical response for treatment-refractory schizophrenic patients. *Am J Psychiatry* 1995; 152:179-182.
6. Taylor D, et al. Doses of carbamazepine and valproate in bipolar affective disorder. *Psychiatric Bulletin* 1997; 21:221-223.
7. Eadie MJ. Anticonvulsant drugs. *Drugs* 1984; 27:328-363.
8. Chbili C, et al. Relationships between pharmacokinetic parameters of carbamazepine and therapeutic response in patients with bipolar disease. *Ann Biol Clin (Paris)* 2014; 72:453-459.
9. Cohen AF, et al. Lamotrigine, a new anticonvulsant: pharmacokinetics in normal humans. *Clin Pharmacol Ther* 1987; 42:535-541.
10. Kilpatrick ES, et al. Concentration-effect and concentration-toxicity relations with lamotrigine: a prospective study. *Epilepsia* 1996; 37:534-538.
11. Johannessen SI, et al. Therapeutic drug monitoring of the newer antiepileptic drugs. *Ther Drug Monit* 2003; 25:347-363.
12. Kagawa S, et al. Relationship between plasma concentrations of lamotrigine and its early therapeutic effect of lamotrigine augmentation therapy in treatment-resistant depressive disorder. *Ther Drug Monit* 2014; 36:730-733.
13. Nakamura A, et al. Prediction of an optimal dose of lamotrigine for augmentation therapy in treatment-resistant depressive disorder from plasma lamotrigine concentration at week 2. *Ther Drug Monit* 2016; 38:379-382.
14. Schou M. Forty years of lithium treatment. *Arch Gen Psychiatry* 1997; 54:9-13.
15. Anon. Using lithium safely. *Drug Ther Bull* 1999; 37:22-24.

16. Nicholson J, et al. Monitoring patients on lithium – a good practice guideline. *Psychiatric Bulletin* 2002; 26:348–351.
17. National Institute for Health and Care Excellence. Bipolar disorder: assessment and management. Clinical guideline [CG185]. 2014 (last updated December 2023, last accessed August 2024); <https://www.nice.org.uk/guidance/cg185>.
18. Severus WE, et al. What is the optimal serum lithium level in the long-term treatment of bipolar disorder – a review? *Bipolar Disord* 2008; 10:231–237.
19. Nolen WA, et al. The association of the effect of lithium in the maintenance treatment of bipolar disorder with lithium plasma levels: a post hoc analysis of a double-blind study comparing switching to lithium or placebo in patients who responded to quetiapine (Trial 144). *Bipolar Disord* 2013; 15:100–109.
20. Nazirizadeh Y, et al. Serum concentrations of paliperidone versus risperidone and clinical effects. *Eur J Clin Pharmacol* 2010; 66:797–803.
21. Schoretsanitis G, et al. A systematic review and combined analysis of therapeutic drug monitoring studies for oral paliperidone. *Expert Rev Clin Pharmacol* 2018; 11:625–639.
22. Taylor D, et al. Plasma levels of tricyclics and related antidepressants: are they necessary or useful? *Psychiatric Bulletin* 1995; 19:548–550.
23. Perucca E. Pharmacological and therapeutic properties of valproate. *CNS Drugs* 2002; 16:695–714.
24. Allen MH, et al. Linear relationship of valproate serum concentration to response and optimal serum levels for acute mania. *Am J Psychiatry* 2006; 163:272–275.
25. Bowden CL, et al. Relation of serum valproate concentration to response in mania. *Am J Psychiatry* 1996; 153:765–770.
26. Vazquez M, et al. Hyperammonemia associated with valproic acid concentrations. *Biomed Res Int* 2014; 2014:217269.
27. Muller MJ, et al. Amisulpride doses and plasma levels in different age groups of patients with schizophrenia or schizoaffective disorder. *J Psychopharmacol* 2008; 23:278–286.
28. Muller MJ, et al. Gender aspects in the clinical treatment of schizophrenic inpatients with amisulpride: a therapeutic drug monitoring study. *Pharmacopsychiatry* 2006; 39:41–46.
29. Bergemann N, et al. Plasma amisulpride levels in schizophrenia or schizoaffective disorder. *Eur Neuropsychopharmacol* 2004; 14:245–250.
30. Muller MJ, et al. Therapeutic drug monitoring for optimizing amisulpride therapy in patients with schizophrenia. *J Psychiatr Res* 2007; 41:673–679.
31. Sparshatt A, et al. Amisulpride – dose, plasma concentration, occupancy and response: implications for therapeutic drug monitoring. *Acta Psychiatr Scand* 2009; 120:416–428.
32. Schoretsanitis G, et al. TDM in psychiatry and neurology: a comprehensive summary of the consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology, update 2017; a tool for clinicians. *World J Biol Psychiatry* 2018; 19:162–174.
33. Jönsson AK, et al. A compilation of serum concentrations of 12 antipsychotic drugs in a therapeutic drug monitoring setting. *Ther Drug Monit* 2019; 41:348–356.
34. Reeves S, et al. Therapeutic window of dopamine D2/3 receptor occupancy to treat psychosis in Alzheimer's disease. *Brain* 2017; 140:1117–1127.
35. Reeves S, et al. Therapeutic D2/3 receptor occupancies and response with low amisulpride blood concentrations in very late-onset schizophrenia-like psychosis (VLOSLP). *Int J Geriatr Psychiatry* 2018; 33:396–404.

36. Bowskill SV, et al. Plasma amisulpride in relation to prescribed dose, clozapine augmentation, and other factors: data from a therapeutic drug monitoring service, 2002–2010. *Hum Psychopharmacol* 2012; 27:507–513.
37. Mace S, et al. Aripiprazole: dose-response relationship in schizophrenia and schizoaffective disorder. *CNS Drugs* 2008; 23:773–780.

876 The Maudsley® Prescribing Guidelines in Psychiatry CHAPTER 11

38. Sparshatt A, et al. A systematic review of aripiprazole – dose, plasma concentration, receptor occupancy and response: implications for therapeutic drug monitoring. *J Clin Psychiatry* 2010; 71:1447–1456.
39. Kirschbaum KM, et al. Therapeutic monitoring of aripiprazole by HPLC with column-switching and spectrophotometric detection. *Clin Chem* 2005; 51:1718–1721.
40. Kirschbaum KM, et al. Serum levels of aripiprazole and dehydroaripiprazole, clinical response and side effects. *World J Biol Psychiatry* 2008; 9:212–218.
41. Molden E, et al. Pharmacokinetic variability of aripiprazole and the active metabolite dehydroaripiprazole in psychiatric patients. *Ther Drug Monit* 2006; 28:744–749.
42. Bachmann CJ, et al. Large variability of aripiprazole and dehydroaripiprazole serum concentrations in adolescent patients with schizophrenia. *Ther Drug Monit* 2008; 30:462–466.
43. Hendset M, et al. Impact of the CYP2D6 genotype on steady-state serum concentrations of aripiprazole and dehydroaripiprazole. *Eur J Clin Pharmacol* 2007; 63:1147–1151.
44. Mallikaarjun S, et al. Pharmacokinetics, tolerability and safety of aripiprazole once-monthly in adult schizophrenia: an open-label, parallel- arm, multiple-dose study. *Schizophr Res* 2013; 150:281–288.
45. Korell J, et al. Determination of plasma concentration reference ranges for oral aripiprazole, olanzapine, and quetiapine. *Eur J Clin Pharmacol* 2018; 74:593–599.
46. Harlin M, et al. Aripiprazole plasma concentrations delivered from two 2-month long-acting injectable formulations: an indirect comparison. *Neuropsychiatr Dis Treat* 2023; 19:1409–1416.
47. Haring C, et al. Influence of patient-related variables on clozapine plasma levels. *Am J Psychiatry* 1990; 147:1471–1475.
48. Haring C, et al. Dose-related plasma levels of clozapine: influence of smoking behaviour, sex and age. *Psychopharmacology* 1989; 99 Suppl:S38–S40.
49. Taylor D. Pharmacokinetic interactions involving clozapine. *Br J Psychiatry* 1997; 171:109–112.
50. Ng CH, et al. An inter-ethnic comparison study of clozapine dosage, clinical response and plasma levels. *Int Clin Psychopharmacol* 2005; 20:163–168.
51. Ruan CJ, et al. Clozapine metabolism in East Asians and Caucasians: a pilot exploration of the prevalence of poor metabolizers and a systematic review. *J Clin Psychopharmacol* 2019; 39:135–144.
52. De Leon J, et al. Do Asian patients require only half of the clozapine dose prescribed for Caucasians? A critical overview. *Indian J Psychol Med* 2020; 42:4–10.
53. Suhas S, et al. Do Indian patients with schizophrenia need half the recommended clozapine dose to achieve therapeutic serum level? An exploratory study. *Schizophr Res* 2020; 222:195–201.
54. Bhattacharya R, et al. Clozapine prescribing: comparison of clozapine dosage and plasma levels between white British and Bangladeshi patients. *BJPsych Bull* 2021; 45:22–27.
55. Ruan CJ, et al. Exploring the prevalence of clozapine phenotypic poor metabolizers in 4 Asian samples: they ranged between 2% and 13. *J Clin Psychopharmacol* 2019; 39:644–648.
56. De Leon J, et al. Using therapeutic drug monitoring to personalize clozapine dosing in Asians. *Asia Pac Psychiatry* 2020; 12:e12384.
57. Rostami-Hodjegan A, et al. Influence of dose, cigarette smoking, age, sex, and metabolic activity on plasma clozapine concentrations: a predictive model and nomograms to aid clozapine dose adjustment and to assess compliance in individual patients. *J Clin Psychopharmacol* 2004; 24:70–78.
58. Taylor D, et al. Predicting clozapine dose required to achieve a therapeutic plasma concentration – a comparison of a population algorithm and three algorithms based on gene variant models. *J Psychopharmacol* 2023; 37:1030–1039.
59. Haack MJ, et al. Toxic rise of

clozapine plasma concentrations in relation to inflammation. *Eur Neuropsychopharmacol* 2003; 13:381–385. 60. De Leon J, et al. Serious respiratory infections can increase clozapine levels and contribute to side effects: a case report. *Prog Neuropsychopharmacol Biol Psychiatry* 2003; 27:1059–1063. 61. Espnes KA, et al. A puzzling case of increased serum clozapine levels in a patient with inflammation and infection. *Ther Drug Monit* 2012; 34:489–492. 62. VanderZwaag C, et al. Response of patients with treatment-refractory schizophrenia to clozapine within three serum level ranges. *Am J Psychiatry* 1996; 153:1579–1584. 63. Perry PJ, et al. Clozapine and norclozapine plasma concentrations and clinical response of treatment refractory schizophrenic patients. *Am J Psychiatry* 1991; 148:231–235. 64. Miller DD. Effect of phenytoin on plasma clozapine concentrations in two patients. *J Clin Psychiatry* 1991; 52:23–25. 65. Spina E, et al. Relationship between plasma concentrations of clozapine and norclozapine and therapeutic response in patients with schizophrenia resistant to conventional neuroleptics. *Psychopharmacology* 2000; 148:83–89. 66. Hasegawa M, et al. Relationship between clinical efficacy and clozapine concentrations in plasma in schizophrenia: effect of smoking. *J Clin Psychopharmacol* 1993; 13:383–390. 67. Potkin SG, et al. Plasma clozapine concentrations predict clinical response in treatment-resistant schizophrenia. *J Clin Psychiatry* 1994; 55 Suppl B:133–136. 68. Perry PJ. Therapeutic drug monitoring of antipsychotics. *Psychopharmacol Bull* 2001; 35:19–29. 69. Llorca PM, et al. Effectiveness of clozapine in neuroleptic-resistant schizophrenia: clinical response and plasma concentrations. *J Psychiatry Neurosci* 2002; 27:30–37. 70. Xiang YQ, et al. Serum concentrations of clozapine and norclozapine in the prediction of relapse of patients with schizophrenia. *Schizophr Res* 2006; 83:201–210.

Pharmacokinetics CHAPTER 11 71. Stieffenhofer V, et al. Clozapine plasma level monitoring for prediction of rehospitalization schizophrenic outpatients. *Pharmacopsychiatry* 2011; 44:55–59. 72. Lee J, et al. Quantifying intraindividual variations in plasma clozapine levels: a population pharmacokinetic approach. *J Clin Psychiatry* 2016; 77:681–687. 73. Turrión MC, et al. Intra-individual variation of clozapine and norclozapine plasma levels in clinical practice. *Rev Psiquiatr Salud Ment* 2020; 13:31–35. 74. Khan AY, et al. Examining concentration-dependent toxicity of clozapine: role of therapeutic drug monitoring. *J Psychiatr Pract* 2005; 11:289–301. 75. Varma S, et al. Clozapine-related EEG changes and seizures: dose and plasma-level relationships. *Ther Adv Psychopharmacol* 2011; 1:47–66. 76. Greenwood-Smith C, et al. Serum clozapine levels: a review of their clinical utility. *J Psychopharmacol* 2003; 17:234–238. 77. Yusufi B, et al. Prevalence and nature of side effects during clozapine maintenance treatment and the relationship with clozapine dose and plasma concentration. *Int Clin Psychopharmacol* 2007; 22:238–243. 78. Remington G, et al. Clozapine and therapeutic drug monitoring: is there sufficient evidence for an upper threshold? *Psychopharmacology (Berl)* 2013; 225:505–518. 79. Bogers J, et al. Feasibility and effect of increasing clozapine plasma levels in long-stay patients with treatment-resistant schizophrenia. *J Clin Psychopharmacol* 2023; 43:97–105. 80. Northwood K, et al. Optimising plasma clozapine levels to improve treatment response: an individual patient data meta-analysis and receiver operating characteristic curve analysis. *Br J Psychiatry* 2023; 222:241–245. 81. Couchman L, et al. Plasma clozapine, norclozapine, and the clozapine:norclozapine ratio in relation to prescribed dose and other factors: data from a therapeutic drug monitoring service, 1993–2007. *Ther Drug Monit* 2010; 32:438–447. 82. Wickramarachchi P, et al. Biological variation in clozapine and metabolite reporting during therapeutic drug monitoring. *Clin Chim Acta* 2022; 531:183–187. 83. Volpicelli SA, et al. Determination of clozapine, norclozapine, and clozapine-N-oxide in serum by liquid chromatography. *Clin Chem* 1993; 39:1656–1659. 84. Guitton C, et al. Clozapine and metabolite

concentrations during treatment of patients with chronic schizophrenia. *J Clin Pharmacol* 1999; 39:721–728. 85. Palego L, et al. Clozapine, norclozapine plasma levels, their sum and ratio in 50 psychotic patients: influence of patient-related variables. *Prog Neuropsychopharmacol Biol Psychiatry* 2002; 26:473–480. 86. Wang CY, et al. The differential effects of steady-state fluvoxamine on the pharmacokinetics of olanzapine and clozapine in healthy volunteers. *J Clin Pharmacol* 2004; 44:785–792. 87. Schoretsanitis G, et al. A comprehensive review of the clinical utility of and a combined analysis of the clozapine/norclozapine ratio in therapeutic drug monitoring for adult patients. *Expert Rev Clin Pharmacol* 2019; 12:603–621. 88. Bishara D, et al. Olanzapine: a systematic review and meta-regression of the relationships between dose, plasma concentration, receptor occupancy, and response. *J Clin Psychopharmacol* 2013; 33:329–335. 89. Aravagiri M, et al. Plasma level monitoring of olanzapine in patients with schizophrenia: determination by high-performance liquid chromatography with electrochemical detection. *Ther Drug Monit* 1997; 19:307–313. 90. Gex-Fabry M, et al. Therapeutic drug monitoring of olanzapine: the combined effect of age, gender, smoking, and comedication. *Ther Drug Monit* 2003; 25:46–53. 91. Bergemann N, et al. Olanzapine plasma concentration, average daily dose, and interaction with co-medication in schizophrenic patients. *Pharmacopsychiatry* 2004; 37:63–68. 92. Perry PJ, et al. Olanzapine plasma concentrations and clinical response in acutely ill schizophrenic patients. *J Clin Psychopharmacol* 1997; 17:472–477. 93. Fellows L, et al. Investigation of target plasma concentration–effect relationships for olanzapine in schizophrenia. *Ther Drug Monit* 2003; 25:682–689. 94. Mauri MC, et al. Clinical outcome and olanzapine plasma levels in acute schizophrenia. *Eur Psychiatry* 2005; 20:55–60. 95. Rao ML, et al. Olanzapine: pharmacology, pharmacokinetics and therapeutic drug monitoring. *Fortschr Neurol Psychiatr* 2001; 69:510–517. 96. Robertson MD, et al. Olanzapine concentrations in clinical serum and postmortem blood specimens – when does therapeutic become toxic? *J Forensic Sci* 2000; 45:418–421. 97. Bech P, et al. Olanzapine plasma level in relation to antimanic effect in the acute therapy of manic states. *Nord J Psychiatry* 2006; 60:181–182. 98. Schoretsanitis G, et al. Blood levels to optimize antipsychotic treatment in clinical practice: a joint consensus statement of the American Society of Clinical Psychopharmacology and the Therapeutic Drug Monitoring Task Force of the Arbeitsgemeinschaft für Neuropsychopharmakologie und Pharmakopsychiatrie. *J Clin Psychiatry* 2020; 81:19cs13169. 99. Noel C. A review of a recently published guidelines’ ‘strong recommendation’ for therapeutic drug monitoring of olanzapine, haloperidol, perphenazine, and fluphenazine. *Ment Health Clin* 2019; 9:287–293. 100. Wesner K, et al. Therapeutic reference range for olanzapine in schizophrenia: systematic review on blood concentrations, clinical effects, and dopamine receptor occupancy. *J Clin Psychiatry* 2023; 84:22r14626. 101. Perry PJ, et al. The association of weight gain and olanzapine plasma concentrations. *J Clin Psychopharmacol* 2005; 25:250–254. 102. Kelly DL, et al. Plasma concentrations of high-dose olanzapine in a double-blind crossover study. *Hum Psychopharmacol* 2006; 21:393–398.

878 The Maudsley® Prescribing Guidelines in Psychiatry CHAPTER 11 103. Patel MX, et al. Plasma olanzapine in relation to prescribed dose and other factors: data from a therapeutic drug monitoring service, 1999–2009. *J Clin Psychopharmacol* 2011; 31:411–417. 104. Tsuboi T, et al. Predicting plasma olanzapine concentration following a change in dosage: a population pharmacokinetic study. *Pharmacopsychiatry* 2015; 48:286–291. 105. Sparshatt A, et al. Relationship between daily dose, plasma concentrations, dopamine receptor occupancy, and clinical response to quetiapine: a review. *J Clin Psychiatry* 2011; 72:1108–1123. 106. Hasselstrom J, et al. Quetiapine serum concentrations in psychiatric patients: the influence of comedication. *Ther Drug Monit* 2004; 26:486–491. 107. Winter HR, et al. Steady-state pharmacokinetic, safety, and

tolerability profiles of quetiapine, norquetiapine, and other quetiapine metabolites in pediatric and adult patients with psychotic disorders. *J Child Adolesc Psychopharmacol* 2008; 18:81–98. 108. Li KY, et al. Multiple dose pharmacokinetics of quetiapine and some of its metabolites in Chinese suffering from schizophrenia. *Acta Pharmacol Sin* 2004; 25:390–394. 109. McConville BJ, et al. Pharmacokinetics, tolerability, and clinical effectiveness of quetiapine fumarate: an open-label trial in adolescents with psychotic disorders. *J Clin Psychiatry* 2000; 61:252–260. 110. Castberg I, et al. Quetiapine and drug interactions: evidence from a routine therapeutic drug monitoring service. *J Clin Psychiatry* 2007; 68:1540–1545. 111. Aichhorn W, et al. Influence of age, gender, body weight and valproate comedication on quetiapine plasma concentrations. *Int Clin Psychopharmacol* 2006; 21:81–85. 112. Mauri MC, et al. Two weeks' quetiapine treatment for schizophrenia, drug-induced psychosis and borderline personality disorder: a naturalistic study with drug plasma levels. *Expert Opin Pharmacother* 2007; 8:2207–2213. 113. Patteet L, et al. Therapeutic drug monitoring of common antipsychotics. *Ther Drug Monit* 2012; 34:629–651. 114. Fisher DS, et al. Plasma concentrations of quetiapine, N-desalkylquetiapine, o-desalkylquetiapine, 7-hydroxyquetiapine, and quetiapine sulfoxide in relation to quetiapine dose, formulation, and other factors. *Ther Drug Monit* 2012; 34:415–421. 115. Sparshatt A, et al. Quetiapine: dose-response relationship in schizophrenia. *CNS Drugs* 2008; 22:49–68. 116. Olesen OV, et al. Serum concentrations and side effects in psychiatric patients during risperidone therapy. *Ther Drug Monit* 1998; 20:380–384. 117. Remington G, et al. A PET study evaluating dopamine D2 receptor occupancy for long-acting injectable risperidone. *Am J Psychiatry* 2006; 163:396–401. 118. Seto K, et al. Risperidone in schizophrenia: is there a role for therapeutic drug monitoring? *Ther Drug Monit* 2011; 33:275–283. 119. Lane HY, et al. Risperidone in acutely exacerbated schizophrenia: dosing strategies and plasma levels. *J Clin Psychiatry* 2000; 61:209–214. 120. Taylor D. Risperidone long-acting injection in practice – more questions than answers? *Acta Psychiatr Scand* 2006; 114:1–2. 121. Nyberg S, et al. Suggested minimal effective dose of risperidone based on PET-measured D2 and 5-HT2A receptor occupancy in schizophrenic patients. *Am J Psychiatry* 1999; 156:869–875. 122. Uchida H, et al. Predicting dopamine D receptor occupancy from plasma levels of antipsychotic drugs: a systematic review and pooled analysis. *J Clin Psychopharmacol* 2011; 31:318–325. 123. Pandina GJ, et al. A randomized, placebo-controlled study to assess the efficacy and safety of 3 doses of paliperidone palmitate in adults with acutely exacerbated schizophrenia. *J Clin Psychopharmacol* 2010; 30:235–244. 124. Mauri MC, et al. Paliperidone long-acting plasma level monitoring and a new method of evaluation of clinical stability. *Pharmacopsychiatry* 2017; 50:145–151. 125. Paletta S, et al. Two years of maintenance therapy with paliperidone long-acting in schizophrenia and schizoaffective disorder: a study with plasma levels. *Eur Neuropsychopharmacol* 2016; 26:S556–S557. 126. Berwaerts J, et al. Efficacy and safety of the 3-month formulation of paliperidone palmitate vs placebo for relapse prevention of schizophrenia: a randomized clinical trial. *JAMA Psychiatry* 2015; 72:830–839. 127. Magnusson MO, et al. Dosing and switching strategies for paliperidone palmitate 3-month formulation in patients with schizophrenia based on population pharmacokinetic modeling and simulation, and clinical trial data. *CNS Drugs* 2017; 31:273–288. 128. T'Jolyn H, et al. Model-informed clinical development of once-every-6-month injection of paliperidone palmitate in patients with schizophrenia: a pharmacometric bridging approach (Part I). *Eur J Drug Metab Pharmacokinet* 2024; 49:477–489. 129. Álamo C. Risperidone ISM as a new option in the clinical management of schizophrenia: a narrative review. *Adv Ther* 2022; 39:4875–4891. 130. Biso L, et al. Therapeutic drug monitoring in psychiatry: enhancing treatment precision and patient outcomes. *Pharmaceuticals (Basel)* 2024; 17:642.

Revision #1

Created 2026-01-04 20:18:08 UTC by Omar Ayman

Updated 2026-01-04 20:18:09 UTC by Omar Ayman